Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRE: Foselutoclax in Diabetic Macular Edema
NCT06011798Phase 2Completed
- Sponsor
- Unity Biotechnology
- Start
- Aug 2023
- Primary completion
- Jan 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of foselutoclax in diabetic macular edema (DME), sponsored by Unity Biotechnology. Started Aug 2023; status: completed.
02
Drugs
foselutoclax
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06011798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06011798.